cAMP signalling in osteoimmune regulation: mechanistic determinants and translational evidence
Year: 2026
Type: article
Abstract: Bone remodelling and repair depend on interactions amongst skeletal, stromal and immune cells, and disruption of these interactions contributes to bone disease. Cyclic adenosine monophosphate (cAMP) signalling transduces endocrine, inflammatory and mechanical cues across osteoblast-lineage cells, osteocytes, osteoclast-lineage cells and immune cells. However, elevated intracellular cAMP does not produce a uniform skeletal response. Receptor identity, the spatial and temporal organisation of cAMP signals, the identity and differentiation state of the responding cell, and downstream effector engagement together influence bone formation, osteoclast differentiation and immune-cell responses. Protein kinase A (PKA) mediates several well-characterised responses, whereas exchange proteins directly activated by cAMP (EPACs) can mediate distinct downstream effects. This review compares the evidence for these mechanisms, distinguishing receptor-associated observations and cAMP elevation from effects experimentally shown to depend on PKA or EPAC. The discussion focuses on osteoporosis, inflammatory bone destruction, including periodontitis-associated alveolar bone loss, and experimental strategies for local bone regeneration. Evidence directly linking cAMP signalling to osteoimmune mechanisms in osteoarthritis and tumour-associated bone disease is less complete. Parathyroid hormone 1 receptor (PTH1R) agonists have established antifracture efficacy in osteoporosis, but this validates receptor-directed treatment rather than isolated PKA activation. Phosphodiesterase 4 (PDE4) inhibition has clinical anti-inflammatory efficacy in psoriatic arthritis, whereas protection against structural bone damage remains unestablished. Adenosine receptor modulation and local or bone-targeted delivery are supported mainly by preclinical skeletal evidence. Further translation will require identification of the responding cell populations, direct assessment of downstream effector involvement and demonstration of benefit using disease-relevant skeletal outcomes. Overall, cAMP signalling is best understood as a context-dependent regulatory network rather than a uniformly anabolic or anti-resorptive pathway.
Source: Frontiers in Immunology
Language: English
Topic: Bone Metabolism and Diseases
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7226030331
